PL2043637T3 - Sposoby i leki do podawania ibuprofenu - Google Patents

Sposoby i leki do podawania ibuprofenu

Info

Publication number
PL2043637T3
PL2043637T3 PL07813027T PL07813027T PL2043637T3 PL 2043637 T3 PL2043637 T3 PL 2043637T3 PL 07813027 T PL07813027 T PL 07813027T PL 07813027 T PL07813027 T PL 07813027T PL 2043637 T3 PL2043637 T3 PL 2043637T3
Authority
PL
Poland
Prior art keywords
ibuprofen
drugs
methods
administering ibuprofen
administering
Prior art date
Application number
PL07813027T
Other languages
English (en)
Polish (pl)
Inventor
George Tidmarsh
Barry L Golombik
Puneet Sharma
Original Assignee
Horizon Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/489,269 external-priority patent/US20080021078A1/en
Priority claimed from US11/489,272 external-priority patent/US20080020040A1/en
Application filed by Horizon Pharma Usa Inc filed Critical Horizon Pharma Usa Inc
Publication of PL2043637T3 publication Critical patent/PL2043637T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07813027T 2006-07-18 2007-07-17 Sposoby i leki do podawania ibuprofenu PL2043637T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/489,269 US20080021078A1 (en) 2006-07-18 2006-07-18 Methods and medicaments for administration of ibuprofen
US11/489,272 US20080020040A1 (en) 2006-07-18 2006-07-18 Unit dose form for administration of ibuprofen
US89737107P 2007-01-24 2007-01-24
PCT/US2007/073716 WO2008011426A2 (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen
EP07813027A EP2043637B8 (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen

Publications (1)

Publication Number Publication Date
PL2043637T3 true PL2043637T3 (pl) 2012-06-29

Family

ID=38957561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07813027T PL2043637T3 (pl) 2006-07-18 2007-07-17 Sposoby i leki do podawania ibuprofenu

Country Status (13)

Country Link
EP (2) EP2438919A1 (OSRAM)
JP (1) JP2009543885A (OSRAM)
AT (1) ATE539747T1 (OSRAM)
AU (1) AU2007275360B2 (OSRAM)
BR (1) BRPI0714937A2 (OSRAM)
CA (1) CA2657928C (OSRAM)
DK (1) DK2043637T3 (OSRAM)
ES (1) ES2380747T3 (OSRAM)
IL (1) IL196425A (OSRAM)
NZ (1) NZ574200A (OSRAM)
PL (1) PL2043637T3 (OSRAM)
PT (1) PT2043637E (OSRAM)
WO (1) WO2008011426A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
US10655183B2 (en) 2014-06-18 2020-05-19 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on ODC1 genotype
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
MA43114A (fr) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) * 2020-07-15 2023-03-01 Schabar Res Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CN117320697A (zh) * 2021-10-21 2023-12-29 韩和制药株式会社 包含孟鲁司特或其药学上可接受的盐和左西替利嗪或其药学上可接受的盐的稳定性提高的薄膜包衣片剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
EP0663839A4 (en) * 1992-09-29 1998-06-03 Merck & Co Inc Ibuprofen-h 2? antagonist combinations.
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
ES2348710T5 (es) * 2001-06-01 2014-02-17 Pozen, Inc. Composiciones farmacéuticas para el suministro coordinado de NSAID
DE10153934A1 (de) 2001-11-06 2003-05-22 Basf Ag Verfahren zur Kristallisation von Profenen
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
US20070043096A1 (en) 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
DE102005049001A1 (de) 2005-10-11 2007-04-12 Basf Ag Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen

Also Published As

Publication number Publication date
PT2043637E (pt) 2012-04-12
EP2043637B1 (en) 2012-01-04
DK2043637T3 (da) 2012-05-07
WO2008011426A2 (en) 2008-01-24
IL196425A (en) 2014-07-31
CA2657928C (en) 2014-12-02
EP2438919A1 (en) 2012-04-11
IL196425A0 (en) 2009-11-18
JP2009543885A (ja) 2009-12-10
EP2043637B8 (en) 2012-03-28
AU2007275360A1 (en) 2008-01-24
ATE539747T1 (de) 2012-01-15
NZ574200A (en) 2011-02-25
AU2007275360B2 (en) 2013-05-16
WO2008011426A3 (en) 2008-12-04
CA2657928A1 (en) 2008-01-24
EP2043637A4 (en) 2009-11-25
BRPI0714937A2 (pt) 2013-03-26
EP2043637A2 (en) 2009-04-08
ES2380747T3 (es) 2012-05-18

Similar Documents

Publication Publication Date Title
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
WO2008064192A3 (en) Modified release analgesic suspensions
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
WO2007098479A3 (en) Localized insulin delivery for bone healing
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2006501240A5 (OSRAM)
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
EP2364144A4 (en) GALENIC FORM FOR INSERTION IN THE MOUTH
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2013541583A5 (OSRAM)
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
NZ597675A (en) Medicament for the long term nsaid use
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.